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LETTER TO THE EDITOR
Oral contraceptive use and breast cancer
Sir - In this issue, McPherson et al. (1987) report a case
control study of oral contraceptive (OC) use and breast
cancer. They concentrated on the 351 pairs of women under
45 years at diagnosis and found a significantly elevated
relative risk (2.6) associated with more than 4 years of use
before the first full term pregnancy. There was, however, no
increase in risk in nulliparous women less than 45 or those
who had used OC before the age of 25. The authors evaluate
their data critically but a number of points appear worthy of
further comment. As they emphasise their results are at
variance with the large study of Stadel et al. (1985) as well
as the five cohort studies (Lipnick et al., 1986) which did not
find such increased risk. On the other hand Meirik et al.
(1986) showed an increased risk in Swedish women under 40
associated with eight or more years of OC use and Pike et al.
(1983) reported an increased risk associated with long term
use of some preparations before the age of 25 whereas the
current authors do not, highlighting the contradictory
conclusions of successive contributions to this field.
Contraceptive history in breast cancer patients is known as
an aetiologically potentially relevant factor so prior to the
study patients may frequently have answered questions on
this subject creating a systematic bias in recall. A control
group of married women does not necessarily have the same
history of sexual activity as ever-married women and the
pattern of former pill use in hospital patients may not be
representative of that of the general population. The controls
in the second part of this study (1980-1984) showed a larger
number with arthritis, skin or musculo-skeletal disorders
than the first part. Although the excess of long term use of
oral contraceptives is not confined to cases matched with
these controls it does account for a major proportion. Oral
contraceptives are known to affect some skin diseases
adversely (RCGP, 1974), former use in controls may
therefore be less. Conversely rheumatoid arthritis, the major
component of 'arthritis/musculo-skeletal disorder' is known
to derive benefit from OC use (Wingrave et al., 1978) which
may be greater in those subjects.
The least plausible conclusion of the study is the adverse
effect of ethinyl oestradiol. Although the peak plasma level
achieved is lower than in those taking mestranol the area
under the concentration/time curve is virtually the same for
mestranol and ethinyl oestradiol (Goldzieher et al., 1980),
and as they are interconverted it is hard to imagine a
differential effect.
The authors hypothesise a latent effect of at least 10 years
between long term early OC exposure and an increased risk
of breast cancer diagnosis based on a theoretical model
(McPherson et al., 1986). It will be important for other
workers to consider this in their experimental designs,
particularly as the data of the present study relate to many
products no longer used and do not incriminate modern low
dose ethinyl oestradiol containing pills. With the above
reservations about bias in this case control study it is not at
all clear that pooled data of different populations over
different time frames will resolve outstanding questions as
the authors suggest.
An uncritical response to the present data may lead to
unjustified anxiety and an unnecessary change of
contraceptive practice or even cessation followed by
unwanted pregnancy as has previously been seen.
Nevertheless similar careful analyses are still needed to
resolve any relationship between breast cancer and OC use.
Yours etc.,
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J.W. Goldzieher, Houston, USA
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A. Haspels, Utrecht, Netherlands
E. Johannisson, Geneva, Switzerland
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M. Potts, North Carolina, USA
(Members, International Committee for Research in
Reproduction)
The findings of McPherson et al. (this issue, p. 653) have been
presented at recent scientific meetings and the manuscript has been
released to interested parties on the authors' own initiative. Shortly
after the receipt of the McPherson paper, the above letter was
received from the International Committee for Research in
Reproduction (ICRR) seeking to place the study in a wider
perspective. The unusual step of simultaneous publication has been
taken in deference to public concern for the issues raised by the
McPherson study and in the interests of serious scientific debate -
Editor.
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